Global Sheep and Goat Pox Vaccines Market Size By Type (Live Vaccines, Killed Vaccines), By Application (Sheep, Goat), By Region, And Segment Forecasts, 2023 to 2032

The Global Sheep and Goat Pox Vaccines Market was valued at USD 320 million in 2023 and is projected to reach USD 610 million by 2031, growing at a CAGR of 8.4% during the forecast period from 2023 to 2031. The increasing prevalence of capripoxvirus infections, rising awareness of livestock immunization, and expanding veterinary healthcare infrastructure are major contributors to the market's growth. Governments and international organizations are actively promoting vaccination programs to curb economic losses in the small ruminant sector, especially in developing regions.

Drivers

1. Increasing Incidence of Capripoxvirus Outbreaks

The rising frequency of sheep and goat pox outbreaks globally is one of the key drivers boosting vaccine demand. These viral infections cause significant morbidity, mortality, and economic losses in livestock populations, prompting veterinary authorities to implement large-scale immunization strategies.

2. Government Initiatives and Mass Vaccination Programs

Government-backed livestock vaccination campaigns, particularly in Asia and Africa, are supporting the growth of the market. Substantial investments in animal health infrastructure and collaboration with international bodies like the FAO and OIE are further encouraging vaccine distribution.

3. Growing Livestock Population and Economic Dependence

Small ruminants serve as a primary source of livelihood in rural communities, especially in emerging economies. This economic dependence is pushing both public and private stakeholders to ensure animal health through preventive vaccination, thereby expanding the vaccine market.

Restraints

1. Limited Access in Remote Areas

Access to proper veterinary care and vaccine distribution channels in underdeveloped or geographically remote regions remains limited, affecting consistent immunization coverage and market penetration.

2. Cold Chain and Storage Constraints

The need for strict cold chain maintenance for vaccine efficacy poses logistical challenges, particularly in countries with weak infrastructure, impacting timely delivery and quality assurance.

Opportunity

1. Development of Thermostable Vaccines and Novel Delivery Systems

Innovations in vaccine formulations, such as thermostable vaccines that do not require refrigeration, and needle-free delivery systems are opening new avenues for expansion in underserved areas.

2. Expanding Veterinary Service Networks in Emerging Economies

The ongoing expansion of veterinary clinics, mobile health units, and government outreach programs in regions like South Asia, Africa, and the Middle East offers immense growth potential for vaccine manufacturers.

Market by System Type Insights

Based on vaccine type, the Live Attenuated Vaccines segment held the largest market share in 2023. These vaccines are widely used due to their long-lasting immunity and cost-effectiveness in mass immunization campaigns. However, the Inactivated Vaccines segment is projected to grow rapidly owing to growing interest in safer alternatives, especially in disease-free zones or regions aiming for eradication.

Market by End-use Insights

By end-use, the Government Veterinary Hospitals segment dominated the market in 2023, driven by mass immunization programs and large-scale procurement by public agencies. The Private Veterinary Clinics segment is also growing steadily, particularly in regions with a higher percentage of commercial livestock operations and a focus on herd health management.

Market by Regional Insights

Geographically, Asia-Pacific led the market in 2023, accounting for the largest revenue share due to high livestock density, recurring outbreaks, and strong government vaccination initiatives in countries such as India, China, and Pakistan. Africa is anticipated to register the fastest CAGR during the forecast period, supported by international aid and increasing focus on animal health in agrarian economies.

Competitive Scenario

Key players in the global sheep and goat pox vaccines market include Indian Immunologicals Ltd., Hester Biosciences, Jordan Bio-Industries Center (JOVAC), Kenya Veterinary Vaccines Production Institute (KEVEVAPI), Bioveta a.s., Onderstepoort Biological Products SOC Ltd., and Vaxxinova. Companies are investing in R&D for thermostable formulations and expanding distribution networks. Strategic collaborations with government agencies and NGOs are also critical in enhancing market presence.

Scope of Work – Global Sheep and Goat Pox Vaccines Market

Key Market Developments

2023: Indian Immunologicals Ltd. launched a new thermostable sheep pox vaccine aimed at improving immunization outreach in remote rural regions.

2024: Hester Biosciences expanded its manufacturing capacity in East Africa to meet the rising demand for livestock vaccines across the continent.

2025: Onderstepoort Biological Products partnered with regional governments in Southern Africa to supply high-volume goat pox vaccines under subsidized schemes.

FAQs

1) What is the current market size of the Global Sheep and Goat Pox Vaccines Market?

The market size in 2023 is estimated at USD 320 million.

2) What is the major growth driver of the Global Sheep and Goat Pox Vaccines Market?

The primary growth driver is the increasing incidence of capripoxvirus outbreaks and government-led mass vaccination initiatives.

3) Which is the largest region during the forecast period in the Global Sheep and Goat Pox Vaccines Market?

Asia-Pacific is the largest regional market, while Africa is expected to grow at the fastest rate.

4) Which segment accounted for the largest market share in Global Sheep and Goat Pox Vaccines Market?

The Live Attenuated Vaccines segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Sheep and Goat Pox Vaccines Market?

Key players include Indian Immunologicals Ltd., Hester Biosciences, JOVAC, KEVEVAPI, Bioveta a.s., and Onderstepoort Biological Products.